Patrys Limited (ASX: PAB) should trade firmer after positive final results from its Phase 1/I2a study in patients with refractory or relapsed multiple myeloma, a type of cancer.
On average each patient had received five prior lines of therapy, including proteasome inhibitors, immunomodulatory drugs or stem cell transplantation.
Twelve patients received 4 intravenous infusions of PAT-SM6, then assessed for a response at 36 days post final treatment.
The primary endpoint of the study was safety and tolerability. At all dose levels tested, PAT-SM6 was well tolerated with no serious adverse events or dose limiting toxicities being reported.
Overall, 4 out of 12 patients treated with PAT-SM6 showed evidence of stabilisation, and had a mean time to next therapy of 51 days, which is considered clinically significant.
Patients who had received prior treatment with proteasome inhibitors responded much better to PAT-SM6 treatment than patients who had been treated with other chemotherapeutics.
This observation is exciting as it indicates that PAT-SM6 may act synergistically with proteasome inhibitors.
This hypothesis will be tested in Patrys’ next clinical trial where PAT-SM6 will be used in combination with Amgen’s Carfilzomib.
In addition, 11 out of 12 patients went on to receive additional salvage therapy after completing the PAT-SM6 clinical trial.
Significantly, 7 of those 11 patients responded very positively, indicating that PAT-SM6 treatment may make cancer cells more sensitive to killing by other chemotherapeutics.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.